Our work on the creation of HSP60 and survivin inhibitors may be appealing, offering a promising line of inquiry for targeted cancer therapy and reduce both the adverse effects and drug resistance while also enhancing the efficiency of targeting cancerous cells. This evidence concerns the gene BIRC5 and cancer.